Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Biofrontera Inc (BFRI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BFRI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -77.1% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.09M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) 89798 | Beta 0.31 | 52 Weeks Range 0.65 - 2.43 | Updated Date 04/2/2025 |
52 Weeks Range 0.65 - 2.43 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-13 | When After Market | Estimate -0.07 | Actual -0.232 |
Profitability
Profit Margin -47.58% | Operating Margin (TTM) -13.63% |
Management Effectiveness
Return on Assets (TTM) -43% | Return on Equity (TTM) -384.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6100271 | Price to Sales(TTM) 0.19 |
Enterprise Value 6100271 | Price to Sales(TTM) 0.19 | ||
Enterprise Value to Revenue 0.16 | Enterprise Value to EBITDA -0.79 | Shares Outstanding 8873930 | Shares Floating 6223910 |
Shares Outstanding 8873930 | Shares Floating 6223910 | ||
Percent Insiders 18.01 | Percent Institutions 31.85 |
Analyst Ratings
Rating 4.5 | Target Price 11.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biofrontera Inc
Company Overview
History and Background
Biofrontera Inc. was founded in 1997. It focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, primarily skin cancer and skin damage caused by sun exposure. The company has grown from a research and development-focused entity to a commercial-stage pharmaceutical company.
Core Business Areas
- Dermatology Products: Development and commercialization of pharmaceuticals for the treatment of skin cancer (specifically actinic keratoses) and sun-damaged skin.
- Ameluzu00ae & BF-RhodoLEDu00ae: Development and commercialization of Ameluzu00ae, a topical prescription drug for photodynamic therapy (PDT) in combination with the BF-RhodoLEDu00ae lamp.
Leadership and Structure
The leadership team includes key executives overseeing areas like research and development, commercial operations, finance, and regulatory affairs. The company has a board of directors responsible for corporate governance and strategic oversight.
Top Products and Market Share
Key Offerings
- Ameluzu00ae: Ameluzu00ae is a topical prescription drug used in photodynamic therapy (PDT) for the treatment of actinic keratoses (AK), a common precancerous skin condition caused by sun exposure. Market share information varies, but Ameluz is a significant player in the PDT market for AK treatment. Competitors include products like Levulan Kerastick (5-aminolevulinic acid) from DUSA Pharmaceuticals and other PDT treatment options and topical creams.
- BF-RhodoLEDu00ae: BF-RhodoLEDu00ae is a medical device (lamp) specifically designed to be used in conjunction with Ameluzu00ae for photodynamic therapy. Its revenue is linked to Ameluz sales. Competitors include other light sources used for PDT treatments, such as blue light lamps.
Market Dynamics
Industry Overview
The dermatology market is driven by aging populations, increasing awareness of skin cancer, and demand for aesthetic treatments. The market for actinic keratosis treatment is growing due to rising incidence rates and improved diagnostic techniques.
Positioning
Biofrontera is positioned as a specialty pharmaceutical company focused on PDT for actinic keratosis. Its competitive advantage lies in its integrated product offering (Ameluzu00ae and BF-RhodoLEDu00ae) and its focus on improving patient outcomes through PDT.
Total Addressable Market (TAM)
The TAM for actinic keratosis treatment is estimated to be in the billions of dollars globally. Biofrontera is positioned to capture a portion of this TAM through continued expansion and product development.
Upturn SWOT Analysis
Strengths
- Specialized focus on PDT for actinic keratosis
- Integrated product offering (Ameluzu00ae and BF-RhodoLEDu00ae)
- Established presence in key markets (e.g., US, Europe)
- Intellectual property protection
Weaknesses
- Reliance on a limited number of products
- Relatively small market capitalization
- Competition from larger pharmaceutical companies
- Dependence on third-party manufacturers and distributors
Opportunities
- Expanding into new geographic markets
- Developing new formulations or indications for Ameluzu00ae
- Acquiring or licensing complementary products
- Increasing awareness of PDT as a treatment option
Threats
- Competition from generic drugs or biosimilars
- Changes in regulatory requirements
- Pricing pressures from payers
- Development of alternative treatment modalities
Competitors and Market Share
Key Competitors
- DUSA (Not Publicly Traded)
- Galderma (Not Publicly Traded)
- Sun Pharmaceutical (SUNPHARMA.NS)
Competitive Landscape
Biofrontera has an advantage with its combined Ameluz/BF-RhodoLED system. However, larger companies have greater resources for marketing and development.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Discuss Biofrontera Inc's growth trends over the past years. Please research recent data as of Q3 2024 is currently unavailable.
Future Projections: Provide projections for Biofrontera Inc's future growth based on analyst estimates. Please research recent data as of Q3 2024 is currently unavailable.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Biofrontera Inc. Please research recent data as of Q3 2024 is currently unavailable.
Summary
Biofrontera is a specialty pharmaceutical company with a focus on PDT for actinic keratosis. Its integrated product offering is a key strength, but it faces competition from larger players. The company's future growth depends on successful market expansion, new product development, and effective management of regulatory and pricing pressures.
Similar Companies
MNKD
MannKind Corp
MNKD
MannKind Corp
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Market share data can be difficult to precisely determine and may be estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.